Effects of denosumab on bone turnover markers in postmenopausal osteoporosis-Reference-Cited by-同舟云学术

Effects of denosumab on bone turnover markers in postmenopausal osteoporosis

Published:2011-02-18 Issue:3 Volume:26 Page:530-537
ISSN:0884-0431
Container-title:Journal of Bone and Mineral Research
language:en
Short-container-title:J Bone Miner Res

Author:

Eastell Richard,Christiansen Claus,Grauer Andreas,Kutilek Stepan,Libanati Cesar,McClung Michael R,Reid Ian R,Resch Heinrich,Siris Ethel,Uebelhart Daniel,Wang Andrea,Weryha Georges,Cummings Steve R

Publisher

Wiley

Subject

Orthopedics and Sports Medicine,Endocrinology, Diabetes and Metabolism

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/jbmr.251/fullpdf

Reference19 articles.

1. Denosumab for prevention of fractures in postmenopausal women with osteoporosis;Cummings;N Engl J Med.,2009

2. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD;Lewiecki;J Bone Miner Res.,2007

3. Denosumab in postmenopausal women with low bone mineral density;McClung;N Engl J Med.,2006

4. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial;Miller;Bone.,2008

5. Effect of denosumab vs alendronate on bone turnover markers and bone mineral density changes at 12 months based on baseline bone turnover level;Brown;J Bone Miner Res.,2008

Cited by 187 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The use of denosumab in osteoporosis – an update on efficacy and drug safety;Expert Opinion on Drug Safety;2024-09-11

2. Hydroxychloroquine and a low antiresorptive activity bisphosphonate conjugate prevent and reverse ovariectomy-induced bone loss in mice through dual antiresorptive and anabolic effects;Bone Research;2024-09-05

3. Efficacy and safety of candidate biosimilar CT-P41 versus reference denosumab: a double-blind, randomized, active-controlled, Phase 3 trial in postmenopausal women with osteoporosis;Osteoporosis International;2024-07-23

4. Denosumab vs. bisphosphonates in primary osteoporosis: a meta-analysis of comparative safety in randomized controlled trials;Osteoporosis International;2024-05-11

5. Risk factors for nonresponse to 2 years of denosumab administration in patients with osteoporosis: A retrospective single‐center cohorts study;Health Science Reports;2024-04